Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer
Status:
Recruiting
Trial end date:
2022-02-20
Target enrollment:
Participant gender:
Summary
This phase Ib trial studies the side effects and best dose of guadecitabine and how well it
works when given together with durvalumab in treating patients with liver, pancreatic, bile
duct, or gallbladder cancer that has spread to other places in the body. Guadecitabine may
stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Monoclonal antibodies, such as durvalumab, may block tumor growth in different ways by
targeting certain cells. Giving guadecitabine and durvalumab may work better in treating
patients with liver, pancreatic, bile duct, or gallbladder cancer.
Phase:
Phase 1
Details
Lead Sponsor:
University of Southern California
Collaborators:
National Cancer Institute (NCI) Van Andel Research Institute